Larisa G. Fechina
Research Subjects
Larisa G. Fechina has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Mikhailovich Popov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
18 shared publications - Grigoriy Anatolyevich Tsaur
Ural State Medical University
16 shared publications - Tatiana Verzhbitskaya
Regional Children’s Hospital
15 shared publications - Olga P. Kovtun
Ural State Medical University
10 shared publications - Galina. A. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
9 shared publications - Yulia Olshanskaya
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
9 shared publications
Latest Publications
- 9 October 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (5)
DEVELOPMENT OF CONSENSUS RECOMMENDATIONS ON THE SURGICAL MANAGEMENT OF PERINEAL SOFT-TISSUE INFECTIONS IN CHILDREN WITH SEVERE CYTOPENIA (MODIFIED DELPHI METHOD)
In children, perineal soft-tissue infections in a state of severe cytopenia due to high-dose chemotherapy and in the early post-transplant period (0–100 days after hematopoietic stem cell transplantation, HSCT) are among the most dangerous infectious complications: in a retrospective analysis of treatment outcomes in 399 children after HSCT, a perianal infection site significantly increased sepsis-related mortality before engraftment (30.8%, p=0.029). The clinical course of such infections in immunocompromised children differs substantially: they are more often polymicrobial (75% vs 58% in immunocompetent patients), and typical pain is frequently blunted, delaying diagnosis. Mortality in necrotizing soft-tissue infections in children reaches 16%. Cases of fulminant spread of inflammation from the external genitalia to the scrotum, perianal tissues, thighs and anterior abdominal wall within 36 hours have been reported. Surgical treatment plays a key role in controlling such infections, yet the specialized surgical literature on the subject is limited mostly to isolated observations and small case series, and current clinical guidelines do not detail surgical tactics for this condition. Given these gaps, we conducted a study using a modified Delphi method aimed at developing consensus recommendations on the surgical management of perineal soft-tissue infections in children in the early post-transplant period. The goal of the work was to standardize the diagnosis and treatment of such patients using contemporary methods, including negative pressure wound therapy. The working group comprised 39 leading pediatric oncosurgeons and transplant specialists from our country; the first-round questionnaire was completed by all 39 experts. The results include 39 statements, of which 37 reached a strong level of consensus, one a moderate level, and one a weak level (published owing to its practical relevance). The recommendations cover the minimum diagnostic work-up for suspected perineal infection after HSCT, principles of the primary operation and staged debridements, wound management and negative pressure wound therapy, indications for colostomy, referral to allied specialists, and timing of reconstructive procedures. We hope that this work will help improve the quality of surgical care for children in the early post-HSCT period and reduce complication and mortality rates.
- 9 October 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (5)
DEVELOPMENT OF CONSENSUS RECOMMENDATIONS ON THE SURGICAL MANAGEMENT OF PERINEAL SOFT-TISSUE INFECTIONS IN CHILDREN WITH SEVERE CYTOPENIA (MODIFIED DELPHI METHOD)
In children, perineal soft-tissue infections in a state of severe cytopenia due to high-dose chemotherapy and in the early post-transplant period (0–100 days after hematopoietic stem cell transplantation, HSCT) are among the most dangerous infectious complications: in a retrospective analysis of treatment outcomes in 399 children after HSCT, a perianal infection site significantly increased sepsis-related mortality before engraftment (30.8%, p=0.029). The clinical course of such infections in immunocompromised children differs substantially: they are more often polymicrobial (75% vs 58% in immunocompetent patients), and typical pain is frequently blunted, delaying diagnosis. Mortality in necrotizing soft-tissue infections in children reaches 16%. Cases of fulminant spread of inflammation from the external genitalia to the scrotum, perianal tissues, thighs and anterior abdominal wall within 36 hours have been reported. Surgical treatment plays a key role in controlling such infections, yet the specialized surgical literature on the subject is limited mostly to isolated observations and small case series, and current clinical guidelines do not detail surgical tactics for this condition. Given these gaps, we conducted a study using a modified Delphi method aimed at developing consensus recommendations on the surgical management of perineal soft-tissue infections in children in the early post-transplant period. The goal of the work was to standardize the diagnosis and treatment of such patients using contemporary methods, including negative pressure wound therapy. The working group comprised 39 leading pediatric oncosurgeons and transplant specialists from our country; the first-round questionnaire was completed by all 39 experts. The results include 39 statements, of which 37 reached a strong level of consensus, one a moderate level, and one a weak level (published owing to its practical relevance). The recommendations cover the minimum diagnostic work-up for suspected perineal infection after HSCT, principles of the primary operation and staged debridements, wound management and negative pressure wound therapy, indications for colostomy, referral to allied specialists, and timing of reconstructive procedures. We hope that this work will help improve the quality of surgical care for children in the early post-HSCT period and reduce complication and mortality rates.
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 159-169
Results of quality control/quality assurance study for the comparability of the results of flow cytometric minimal residual disease studies in B-lineage acute lymphoblastic leukemia in Russian laboratories of the Moscow–Berlin study group
Aim of the study – comparison of results of flow cytometric minimal residual disease (MRD) detection in B-lineage acute lymphoblastic leukemia in two Russian laboratories of the Moscow–Berlin study group. Materials and methods. Ring trial was performed in three rounds. Four flow cytometry specialist from Dmitry Rogachev Center (Moscow) and two from Regional Children Hospital (Ekaterinburg) were suggested to analyze cytometric files of 70 studies of bone marrow samples obtained at various time-points during different treatment phases. Results and discussion. Although false-positive and false-negative results were obtained by single specialists in exact cases, the overall comparability of MRD data was very high. Found discrepancies were observed mainly in cases with very low MRD burden (below 0.01%). Also discordant results were observed in patients with CD10-negative immunophenotype. Nevertheless, in all samples the majority of the documented results were right. Presence of the most experienced expert in each laboratory, who is responsible for the final conclusion on MRD samples, led to the high inter-laboratory concordance. Conclusion. Therefore, discussion of all complicated cases with the most experienced specialists, centralization of the primary immunophenotyping, clinical application of the most reproducible MRD thresholds, as well as further improvement of flow cytometry methodology and technology harmonization will allow achieving perfect reproducibility of the flow cytometric MRD detection in patients with B-lineage acute lymphoblastic leukemia.
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 159-169
Open AccessResults of quality control/quality assurance study for the comparability of the results of flow cytometric minimal residual disease studies in B-lineage acute lymphoblastic leukemia in Russian laboratories of the Moscow–Berlin study group
Aim of the study – comparison of results of flow cytometric minimal residual disease (MRD) detection in B-lineage acute lymphoblastic leukemia in two Russian laboratories of the Moscow–Berlin study group. Materials and methods. Ring trial was performed in three rounds. Four flow cytometry specialist from Dmitry Rogachev Center (Moscow) and two from Regional Children Hospital (Ekaterinburg) were suggested to analyze cytometric files of 70 studies of bone marrow samples obtained at various time-points during different treatment phases. Results and discussion. Although false-positive and false-negative results were obtained by single specialists in exact cases, the overall comparability of MRD data was very high. Found discrepancies were observed mainly in cases with very low MRD burden (below 0.01%). Also discordant results were observed in patients with CD10-negative immunophenotype. Nevertheless, in all samples the majority of the documented results were right. Presence of the most experienced expert in each laboratory, who is responsible for the final conclusion on MRD samples, led to the high inter-laboratory concordance. Conclusion. Therefore, discussion of all complicated cases with the most experienced specialists, centralization of the primary immunophenotyping, clinical application of the most reproducible MRD thresholds, as well as further improvement of flow cytometry methodology and technology harmonization will allow achieving perfect reproducibility of the flow cytometric MRD detection in patients with B-lineage acute lymphoblastic leukemia.
- Open Access
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 14-36
Interim results of a multicenter study of treatment of patients with acute myeloid leukemia according to the AML-MRD-2018 protocol
Introduction. Acute myeloid leukemia (AML) is the second most prevalent type of blood malignancy in children that accounts for 15–20% of all pediatric leukemia cases. Before 2018, large-scale prospective studies of AML in children in the Russian Federation were constrained by the absence of both a central pathology review system and centralized monitoring of minimal residual disease (MRD). To address these issues, the national protocol AML-MRD-2018 (NCT03846362) was developed and initiated by the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Materials and methods. This study included 631 patients from 54 clinical facilities across 48 regions of the Russian Federation. Central pathology review was performed at two institutions: the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) and Yekaterinburg Regional Children's Clinical Hospital. Risk group stratification was performed in two steps: initially it was based on molecular and genetic characteristics of blast cells, and then (for intermediate risk group) – on response to treatment assessed by MRD testing. Criteria for primary refractoriness and the transfer of patients to a high-risk group were blast cell count (assessed morphologically and immunophenotypically) 5% after induction and MRD ≥ 0.1% after the first course of consolidation. The final stratification was as follows: 67 standard-risk patients, 251 intermediate-risk patients, and 313 high-risk patients. Results. Response to induction therapy was assessable in 580 patients; complete remission was achieved in 84.3% of the cases (n = 489). Treatment effectiveness varied significantly across the risk groups: it was 100% in the standard-risk group (all the patients achieved MRD-negative remission), 91.5% in the intermediate-risk group and 72.9% in the high-risk group (which had the highest proprotion of refractory and MRD positive patients). The first cycle of consolidation therapy according to the protocol was given to 385 patients from the intermediate- and high-risk groups; MRD assessment was performed in 348 cases. MRD-negative remission was achieved in 196 (96%) out of 204 MRD-assessed patients in the intermediate-risk group and in 129 (90%) out of 144 MRD-assessed patients in the high-risk group. The 3-year treatment outcomes in the whole cohort of patients (n = 631) were the following: the overall survival (OS) reached 71% (95% confidence interval (CI) 68–76), the event-free survival (EFS) was 44% (95% CI 40–48), the cumulative risk of relapse (CRR) was 36% (95% CI 31–41). There were significant differences in these parameters between the risk-groups: standard-risk group (n = 67): OS – 84%, EFS – 66%, CRR – 24%; intermediate-risk group (n = 251): OS – 77%, EFS – 50%, CRR – 38%; high-risk group (n = 313): OS – 64%, EFS – 34%, CRR – 37%. Over the period of observation, a total of 255 allogeneic hematopoietic stem cell transplantations (HSCT) were performed. The most common HSCTs were from haploidentical related donors (n = 180; 70%), the graft sources were peripheral blood stem cells (n = 138) and bone marrow (n = 87). The median time from start of therapy to HSCT was 5 months. The 2-year EFS after HSCT was 65% and the 2-year OS post-HSCT was 75%. Conclusion. To date, the potential of universal chemotherapy protocols for AML has been exhausted. Further improvements in treatment outcomes are only possible through the implementation of individualized treatment strategies based on molecular genetic profiling. Promising approaches include the addition of FLT3 inhibitors, gemtuzumab ozogamicin, venetoclax; the inclusion of menin inhibitors in leukemias with KMT2A rearrangements; the integration of hypomethylating agents in the treatment of patients with CBF-AML.
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 14-36
Open AccessInterim results of a multicenter study of treatment of patients with acute myeloid leukemia according to the AML-MRD-2018 protocol
Introduction. Acute myeloid leukemia (AML) is the second most prevalent type of blood malignancy in children that accounts for 15–20% of all pediatric leukemia cases. Before 2018, large-scale prospective studies of AML in children in the Russian Federation were constrained by the absence of both a central pathology review system and centralized monitoring of minimal residual disease (MRD). To address these issues, the national protocol AML-MRD-2018 (NCT03846362) was developed and initiated by the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Materials and methods. This study included 631 patients from 54 clinical facilities across 48 regions of the Russian Federation. Central pathology review was performed at two institutions: the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) and Yekaterinburg Regional Children's Clinical Hospital. Risk group stratification was performed in two steps: initially it was based on molecular and genetic characteristics of blast cells, and then (for intermediate risk group) – on response to treatment assessed by MRD testing. Criteria for primary refractoriness and the transfer of patients to a high-risk group were blast cell count (assessed morphologically and immunophenotypically) 5% after induction and MRD ≥ 0.1% after the first course of consolidation. The final stratification was as follows: 67 standard-risk patients, 251 intermediate-risk patients, and 313 high-risk patients. Results. Response to induction therapy was assessable in 580 patients; complete remission was achieved in 84.3% of the cases (n = 489). Treatment effectiveness varied significantly across the risk groups: it was 100% in the standard-risk group (all the patients achieved MRD-negative remission), 91.5% in the intermediate-risk group and 72.9% in the high-risk group (which had the highest proprotion of refractory and MRD positive patients). The first cycle of consolidation therapy according to the protocol was given to 385 patients from the intermediate- and high-risk groups; MRD assessment was performed in 348 cases. MRD-negative remission was achieved in 196 (96%) out of 204 MRD-assessed patients in the intermediate-risk group and in 129 (90%) out of 144 MRD-assessed patients in the high-risk group. The 3-year treatment outcomes in the whole cohort of patients (n = 631) were the following: the overall survival (OS) reached 71% (95% confidence interval (CI) 68–76), the event-free survival (EFS) was 44% (95% CI 40–48), the cumulative risk of relapse (CRR) was 36% (95% CI 31–41). There were significant differences in these parameters between the risk-groups: standard-risk group (n = 67): OS – 84%, EFS – 66%, CRR – 24%; intermediate-risk group (n = 251): OS – 77%, EFS – 50%, CRR – 38%; high-risk group (n = 313): OS – 64%, EFS – 34%, CRR – 37%. Over the period of observation, a total of 255 allogeneic hematopoietic stem cell transplantations (HSCT) were performed. The most common HSCTs were from haploidentical related donors (n = 180; 70%), the graft sources were peripheral blood stem cells (n = 138) and bone marrow (n = 87). The median time from start of therapy to HSCT was 5 months. The 2-year EFS after HSCT was 65% and the 2-year OS post-HSCT was 75%. Conclusion. To date, the potential of universal chemotherapy protocols for AML has been exhausted. Further improvements in treatment outcomes are only possible through the implementation of individualized treatment strategies based on molecular genetic profiling. Promising approaches include the addition of FLT3 inhibitors, gemtuzumab ozogamicin, venetoclax; the inclusion of menin inhibitors in leukemias with KMT2A rearrangements; the integration of hypomethylating agents in the treatment of patients with CBF-AML.
- 8 April 2026
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 15 (1)
Comparative study of the commercial tests detecting frequent mutations in JAK2 and MPL
Background. qPCR is widely used to detect JAK2 V617F and MPL W515L/K mutations in myeloproliferative neoplasms. This study evaluated the diagnostic performance of four commercially available Russian qPCR test systems. Methods. 45 positive DNA samples (allelic burden 2—45%) and 18 negative samples were analyzed. Target allele frequencies were established using ddPCR as mean from 5 replicates. Two laboratories tested the kits (manufactured by «Genetechnology» LLC, «Formula gena» LLC, «Inogene» LLC, «Syntol» LLC) as independent participants and they were supplied from a manufacturer’s blinded, centralized purchase. Results. Specificity was 100% for all kits. JAK2 V617F: Sensitivity was 96.7% for three out of four kits, but 86.7% for «Genetechnology». «Syntol» kit showed the largest proportional systematic error (β1=1.63), while «Inogene» kit showed none (β1=1.00). «Genetechnology» kit had the highest coefficient of variation (CV=59.8%); «Syntol» kit had the lowest one (CV=10.2%). For MPL W515L mutation detection « Genetechnology « kit displayed both proportional (β1=0.25) and constant (β0=38.34) systematic errors with CV=14.1%. «Inogene» kit showed only a proportional error β1=0.66 and CV=9.4%. For MPL W515K mutation «Genetechnology» kit had a constant error β0=38.83 and CV=13.5%. «Inogene» kit showed a proportional error β1=1.45 and CV=8.9%. Conclusion. For JAK2 V617F mutation detection, the «Formula gena» kit showed the lowest deviation from the target value. For MPL W515L/K mutations, the tests from «Inogene» and «Genetechnology» provided comparable results.
- 8 April 2026
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 15 (1)
Comparative study of the commercial tests detecting frequent mutations in JAK2 and MPL
Background. qPCR is widely used to detect JAK2 V617F and MPL W515L/K mutations in myeloproliferative neoplasms. This study evaluated the diagnostic performance of four commercially available Russian qPCR test systems. Methods. 45 positive DNA samples (allelic burden 2—45%) and 18 negative samples were analyzed. Target allele frequencies were established using ddPCR as mean from 5 replicates. Two laboratories tested the kits (manufactured by «Genetechnology» LLC, «Formula gena» LLC, «Inogene» LLC, «Syntol» LLC) as independent participants and they were supplied from a manufacturer’s blinded, centralized purchase. Results. Specificity was 100% for all kits. JAK2 V617F: Sensitivity was 96.7% for three out of four kits, but 86.7% for «Genetechnology». «Syntol» kit showed the largest proportional systematic error (β1=1.63), while «Inogene» kit showed none (β1=1.00). «Genetechnology» kit had the highest coefficient of variation (CV=59.8%); «Syntol» kit had the lowest one (CV=10.2%). For MPL W515L mutation detection « Genetechnology « kit displayed both proportional (β1=0.25) and constant (β0=38.34) systematic errors with CV=14.1%. «Inogene» kit showed only a proportional error β1=0.66 and CV=9.4%. For MPL W515K mutation «Genetechnology» kit had a constant error β0=38.83 and CV=13.5%. «Inogene» kit showed a proportional error β1=1.45 and CV=8.9%. Conclusion. For JAK2 V617F mutation detection, the «Formula gena» kit showed the lowest deviation from the target value. For MPL W515L/K mutations, the tests from «Inogene» and «Genetechnology» provided comparable results.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Belumosudil in the treatment of steroid-refractory chronic graft-versus-host disease in children: the combined experience of nine centers of the Russian Federation
Introduction. Chronic graft-versus-host disease (cGVHD) remains a serious complication of allogeneic hematopoietic stem cell transplantation in children. In steroid-refractory cases, the prognosis is still unfavorable, and data on the use of the selective ROCK2 inhibitor belumosudil in the pediatric population, particularly in children under 12 years of age, are limited. Materials and methods . A retrospective multicenter analysis was conducted on 43 patients aged ≤ 18 years with steroid-refractory or steroiddependent cGVHD (2014 NIH criteria) who received belumosudil in 9 transplant centers across the Russian Federation between 2023 and 2025. The dose of the drug was determined by the patient's body weight, ranging from 50 to 200 mg/day. The evaluation included the rate and speed of achieving an overall response (complete and partial responses), organ-specific efficacy, safety profile, as well as the frequency of dose reduction, temporary interruptions, and treatment discontinuation. Results. The median age of patients at the start of therapy was 12 years (range: 2–18 years). The median number of prior lines of therapy was 3. An overall response was achieved in 65 % of patients (28/43): a complete response in 5 % (2/43) and a partial response in 60 % (26/43). The highest rates of organ-specific responses were observed in lung involvement (79.5 %), gastrointestinal tract (64 %), oral mucosa, and eyes (65.5 % and 68.5 %, respectively). The median time to response was 35 days. Adverse events of any grade were reported in 70 % of patients, with serious events occurring in 37 %. The most frequent were infectious complications (56 %), hematological toxicity (37 %), and hepatotoxicity (21 %). Dose reduction was required in 35 % of patients, a temporary interruption in 21 %, and treatment discontinuation in 19 %. Conclusion . Belumosudil demonstrated clinically significant efficacy and a manageable safety profile in pediatric patients with severe steroid-refractory cGVHD, including children under 12 years of age. The data obtained add to the limited global publications on the use of belumosudil in pediatrics and support the feasibility of conducting prospective studies.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Belumosudil in the treatment of steroid-refractory chronic graft-versus-host disease in children: the combined experience of nine centers of the Russian Federation
Introduction. Chronic graft-versus-host disease (cGVHD) remains a serious complication of allogeneic hematopoietic stem cell transplantation in children. In steroid-refractory cases, the prognosis is still unfavorable, and data on the use of the selective ROCK2 inhibitor belumosudil in the pediatric population, particularly in children under 12 years of age, are limited. Materials and methods . A retrospective multicenter analysis was conducted on 43 patients aged ≤ 18 years with steroid-refractory or steroiddependent cGVHD (2014 NIH criteria) who received belumosudil in 9 transplant centers across the Russian Federation between 2023 and 2025. The dose of the drug was determined by the patient's body weight, ranging from 50 to 200 mg/day. The evaluation included the rate and speed of achieving an overall response (complete and partial responses), organ-specific efficacy, safety profile, as well as the frequency of dose reduction, temporary interruptions, and treatment discontinuation. Results. The median age of patients at the start of therapy was 12 years (range: 2–18 years). The median number of prior lines of therapy was 3. An overall response was achieved in 65 % of patients (28/43): a complete response in 5 % (2/43) and a partial response in 60 % (26/43). The highest rates of organ-specific responses were observed in lung involvement (79.5 %), gastrointestinal tract (64 %), oral mucosa, and eyes (65.5 % and 68.5 %, respectively). The median time to response was 35 days. Adverse events of any grade were reported in 70 % of patients, with serious events occurring in 37 %. The most frequent were infectious complications (56 %), hematological toxicity (37 %), and hepatotoxicity (21 %). Dose reduction was required in 35 % of patients, a temporary interruption in 21 %, and treatment discontinuation in 19 %. Conclusion . Belumosudil demonstrated clinically significant efficacy and a manageable safety profile in pediatric patients with severe steroid-refractory cGVHD, including children under 12 years of age. The data obtained add to the limited global publications on the use of belumosudil in pediatrics and support the feasibility of conducting prospective studies.
- 25 November 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (3)
Pediatric B-lineage acute lymphoblastic leukemia with CRLF2 rearrangements. Own experience in molecular genetic diagnostics and patient monitoring
B-lineage acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements is characterized by high genetic heterogeneity and can be accompanied with mutations in the JAK-STAT signaling pathway, intrachromosomal amplification of chromosome 21 (iAMP21), dic (9;20), as well as IKZF1 deletions and has an unfavorable outome. Purpose. To characterize clinical, immunological and molecular genetic features of children with B-lineage ALL with CRLF2 rearrangements. Materials and methods. The study included 958 children aged 1-18 years with primarily diagnosed B-lineage ALL. Among them, a search for CRLF2 rearrangements was carried out using the fluorescence in situ hybridization, and the spectrum of genetic aberrations was analyzed using multiplex ligase-dependent probe amplification (MLPA) and targeted next-generation sequencing of RNA. Results. CRLF2 rearrangements were detected in 58 (6.1%) patients, including 42 with P2RY8::CRLF2 (72.4%) and 16 with IGH::CRLF2 (27.6%). Patients with IGH::CRLF2 fusion gene were significantly older, more often had an initial WBC ≥50×109/L and were significantly more often classified as high-risk according to the criteria of the US National Cancer Institute, however no significant differences in survival and cumulative incidence of relapse between these groups were found. JAK1/2 mutations were detected in 14.0% of CRLF2-rearranged patients, RAS family gene mutations in 23.3% and PAX5 alterations (both point mutations and fusion genes) in 18.6%. Seventeen patients (37.7%) with IKZF1 deletions were identified, while 10 of them (22.2%) had the IKZF1plus profile. With a median follow-up time of 5.3 years, the event-free survival of patients with ALL and CRLF2 rearrangements was 0.49 (standard error (SE) 0.22) and the cumulative incidence of relapse was 0.46 (SE 0.12). The most unfavorable outcome was observed in patients with IKZF1plus profile. Of note, the persistence of minimal residual disease at the end of remission induction did not have a statistically significant impact on the prognosis of patients with ALL and CRLF2 rearrangements. Conclusions. In our cohort of pediatric patients with B-lineage ALL the incidence of CRLF2 rearrangements was 6.1%. These patients showed significant genetic heterogeneity and unfavorable outcome.
- 25 November 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (3)
Pediatric B-lineage acute lymphoblastic leukemia with CRLF2 rearrangements. Own experience in molecular genetic diagnostics and patient monitoring
B-lineage acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements is characterized by high genetic heterogeneity and can be accompanied with mutations in the JAK-STAT signaling pathway, intrachromosomal amplification of chromosome 21 (iAMP21), dic (9;20), as well as IKZF1 deletions and has an unfavorable outome. Purpose. To characterize clinical, immunological and molecular genetic features of children with B-lineage ALL with CRLF2 rearrangements. Materials and methods. The study included 958 children aged 1-18 years with primarily diagnosed B-lineage ALL. Among them, a search for CRLF2 rearrangements was carried out using the fluorescence in situ hybridization, and the spectrum of genetic aberrations was analyzed using multiplex ligase-dependent probe amplification (MLPA) and targeted next-generation sequencing of RNA. Results. CRLF2 rearrangements were detected in 58 (6.1%) patients, including 42 with P2RY8::CRLF2 (72.4%) and 16 with IGH::CRLF2 (27.6%). Patients with IGH::CRLF2 fusion gene were significantly older, more often had an initial WBC ≥50×109/L and were significantly more often classified as high-risk according to the criteria of the US National Cancer Institute, however no significant differences in survival and cumulative incidence of relapse between these groups were found. JAK1/2 mutations were detected in 14.0% of CRLF2-rearranged patients, RAS family gene mutations in 23.3% and PAX5 alterations (both point mutations and fusion genes) in 18.6%. Seventeen patients (37.7%) with IKZF1 deletions were identified, while 10 of them (22.2%) had the IKZF1plus profile. With a median follow-up time of 5.3 years, the event-free survival of patients with ALL and CRLF2 rearrangements was 0.49 (standard error (SE) 0.22) and the cumulative incidence of relapse was 0.46 (SE 0.12). The most unfavorable outcome was observed in patients with IKZF1plus profile. Of note, the persistence of minimal residual disease at the end of remission induction did not have a statistically significant impact on the prognosis of patients with ALL and CRLF2 rearrangements. Conclusions. In our cohort of pediatric patients with B-lineage ALL the incidence of CRLF2 rearrangements was 6.1%. These patients showed significant genetic heterogeneity and unfavorable outcome.
- Open Access
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 63-72
Tandem hematopoietic stem cell transplantation in children with solid tumors in the Russian Federation: results of a retrospective multicenter study
Relevance. Despite the overall decline in the use of auto-HSCT, there remains a need for treatment intensification in pediatric patients with highrisk solid tumors. Tandem auto-HSCT represents a promising approach to improve therapeutic efficacy, but its toxicity and impact on long-term outcomes require further investigation, particularly in the Russian patient population.The aim of study – to evaluate the feasibility, toxicity, and long-term outcomes of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) in children with high-risk solid malignant neoplasms in the Russian Federation.Materials and methods. This retrospective multicenter study included 108 (100 %) pediatric patients (median age – 2 years) with solid malignant neoplasms who underwent tandem high-dose chemotherapy with auto-HSCT at 9 centers in the Russian Federation (2004–2024). Main diagnoses included brain tumors – n = 66 (61.1 %), germ cell tumors – n = 25 (23 %), and neuroblastoma – n = 12 (11.1 %). Toxicity was assessed using CTCAE v5.0 criteria, and survival analysis was performed using the Kaplan–Meyer method.Results. The most common complications were febrile neutropenia (88.9 %) and oropharyngeal mucositis (87.1 %), with severe toxicities (Grade 3–4) being rare. The 3-year overall survival was 72.2 %, and event-free survival was 62.7 %.Conclusion. The study demonstrated that tandem auto-HSCT is a feasible procedure with manageable toxicity. These findings suggest the potential of tandem auto-HSCT for children with high-risk solid tumors, though further prospective studies with long-term outcome assessments are needed to define optimal indications.
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 63-72
Open AccessTandem hematopoietic stem cell transplantation in children with solid tumors in the Russian Federation: results of a retrospective multicenter study
Relevance. Despite the overall decline in the use of auto-HSCT, there remains a need for treatment intensification in pediatric patients with highrisk solid tumors. Tandem auto-HSCT represents a promising approach to improve therapeutic efficacy, but its toxicity and impact on long-term outcomes require further investigation, particularly in the Russian patient population.The aim of study – to evaluate the feasibility, toxicity, and long-term outcomes of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) in children with high-risk solid malignant neoplasms in the Russian Federation.Materials and methods. This retrospective multicenter study included 108 (100 %) pediatric patients (median age – 2 years) with solid malignant neoplasms who underwent tandem high-dose chemotherapy with auto-HSCT at 9 centers in the Russian Federation (2004–2024). Main diagnoses included brain tumors – n = 66 (61.1 %), germ cell tumors – n = 25 (23 %), and neuroblastoma – n = 12 (11.1 %). Toxicity was assessed using CTCAE v5.0 criteria, and survival analysis was performed using the Kaplan–Meyer method.Results. The most common complications were febrile neutropenia (88.9 %) and oropharyngeal mucositis (87.1 %), with severe toxicities (Grade 3–4) being rare. The 3-year overall survival was 72.2 %, and event-free survival was 62.7 %.Conclusion. The study demonstrated that tandem auto-HSCT is a feasible procedure with manageable toxicity. These findings suggest the potential of tandem auto-HSCT for children with high-risk solid tumors, though further prospective studies with long-term outcome assessments are needed to define optimal indications.
- Open Access
- 8 April 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 14-25
Preliminary results of treatment of intermediate-risk patients according to the AML-MRD-2018 protocol
In the past decades, significant advancements have been made in the treatment of children with acute myeloid leukemia (AML) with the introduction of more effective treatment regimens, extended indications for hematopoietic stem cell transplantation as well as better supportive therapy and prophylaxis of infectious complications. Nevertheless, an improvement in treatment outcomes is still an important goal. One of the key ways to enhance treatment effectiveness is risk stratification of AML patients based on molecular and genetic characteristics of the disease. A multicenter treatment protocol (the AML-MRD-2018 protocol) was developed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Our study includes 525 patients from 54 Russian hospitals who underwent treatment from November 2018 to December 2023. A total of 205 patients with a median age of 8.9 years (1 month – 17.6 years) were re-stratified to the intermediate-risk group. The 3-year overall and event-free survival for this group was 77% and 47%, respectively. The patients with biallelic CEBPA (dCEBPA) mutations had the most favorable prognosis. In the intermediate-risk group, early death before remission occurred in 6% of the patients; 8% of the patients died in first remission. Death of progressive disease occurred in 32% of all the deceased patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation.
- 8 April 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 14-25
Open AccessPreliminary results of treatment of intermediate-risk patients according to the AML-MRD-2018 protocol
In the past decades, significant advancements have been made in the treatment of children with acute myeloid leukemia (AML) with the introduction of more effective treatment regimens, extended indications for hematopoietic stem cell transplantation as well as better supportive therapy and prophylaxis of infectious complications. Nevertheless, an improvement in treatment outcomes is still an important goal. One of the key ways to enhance treatment effectiveness is risk stratification of AML patients based on molecular and genetic characteristics of the disease. A multicenter treatment protocol (the AML-MRD-2018 protocol) was developed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Our study includes 525 patients from 54 Russian hospitals who underwent treatment from November 2018 to December 2023. A total of 205 patients with a median age of 8.9 years (1 month – 17.6 years) were re-stratified to the intermediate-risk group. The 3-year overall and event-free survival for this group was 77% and 47%, respectively. The patients with biallelic CEBPA (dCEBPA) mutations had the most favorable prognosis. In the intermediate-risk group, early death before remission occurred in 6% of the patients; 8% of the patients died in first remission. Death of progressive disease occurred in 32% of all the deceased patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation.
- 8 April 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (1)
Automated method for measuring L-asparaginase activity
The main goal of L-asparaginase therapy in acute lymphoblastic leukemia (ALL) is complete depletion of asparagine in the blood and cerebrospinal fluid, accompanied by the death of tumor blasts. Asparagine is difficult to measure reliably due to its rapid degradation ex vivo. Serum asparaginase activity correlates well with asparagine depletion. International guidelines clearly state the need for therapeutic drug monitoring (TDM) of asparaginase activity in the blood to improve clinical outcomes in the treatment of patients with ALL. The aim of the article is to describe the adaptation of the method for measuring asparaginase activity in blood serum on a modern biochemical analyzer for use in everyday clinical practice of TDM. Materials and methods. Asparaginase activity was determined using the method of coupled enzymatic reactions accompanied by oxidation of reduced β-nicotinamide adenine dinucleotide (NADH) and a decrease in absorption at a wavelength of 340 nm. The rate of absorption decrease is proportional to the asparaginase activity in the test sample. All measurements were performed on an automatic biochemical analyzer AU 480 (Beckman Coulter). Results of the method adaptation for measurements on an automatic biochemical analyzer: limit of detection (LoD)=7.3 IU/L, lower limit of quantification (LoQ)=13.0 IU/L. Intra-assay precision was 2.1 and 0.97%, respectively, for control samples with an activity of 81.6 and 571.4 IU/L. Inter-assay precision for these control sera was 6.4 and 5.5%, respectively. Conclusion. The analytical characteristics of the method meet the requirements for bioanalytical methods and are close to those established in the work that we took as a basis for adaptation. The automated method allows for the full implementation of real-time TDM of asparaginase in patients with ALL.
- 8 April 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (1)
Automated method for measuring L-asparaginase activity
The main goal of L-asparaginase therapy in acute lymphoblastic leukemia (ALL) is complete depletion of asparagine in the blood and cerebrospinal fluid, accompanied by the death of tumor blasts. Asparagine is difficult to measure reliably due to its rapid degradation ex vivo. Serum asparaginase activity correlates well with asparagine depletion. International guidelines clearly state the need for therapeutic drug monitoring (TDM) of asparaginase activity in the blood to improve clinical outcomes in the treatment of patients with ALL. The aim of the article is to describe the adaptation of the method for measuring asparaginase activity in blood serum on a modern biochemical analyzer for use in everyday clinical practice of TDM. Materials and methods. Asparaginase activity was determined using the method of coupled enzymatic reactions accompanied by oxidation of reduced β-nicotinamide adenine dinucleotide (NADH) and a decrease in absorption at a wavelength of 340 nm. The rate of absorption decrease is proportional to the asparaginase activity in the test sample. All measurements were performed on an automatic biochemical analyzer AU 480 (Beckman Coulter). Results of the method adaptation for measurements on an automatic biochemical analyzer: limit of detection (LoD)=7.3 IU/L, lower limit of quantification (LoQ)=13.0 IU/L. Intra-assay precision was 2.1 and 0.97%, respectively, for control samples with an activity of 81.6 and 571.4 IU/L. Inter-assay precision for these control sera was 6.4 and 5.5%, respectively. Conclusion. The analytical characteristics of the method meet the requirements for bioanalytical methods and are close to those established in the work that we took as a basis for adaptation. The automated method allows for the full implementation of real-time TDM of asparaginase in patients with ALL.
- 30 November 2024
- Published by OOO "Opponent" in Медицинский оппонент
- Vol. 27 (3(27)) , 10-15
Диагностические и прогностические цитокиновые маркеры винкристиновой полиневропатии у детей с острым лимфобластным лейкозом. Ковтун О.П., Корякина О.В., Базарный В.В.
Цель исследования заключалась в определении цитокинов плазмы крови и ликвора, претендующих на роль потенциальных диагностических и прогностических маркеров винкристиновой полиневропатии у детей с острым лимфобластным лейкозом. На основании полученных результатов установлены изменения содержания плазменных и ликворных цитокинов в группе пациентов с винкристиновой полиневропатией, что свидетельствует об их связи с развитием данного нейротоксического расстройства. Для совершенствования комплекса обследования детей с винкристиновой полиневропатией разработана диагностическая панель с оптимальным набором цитокинов.
- 30 November 2024
- Published by OOO "Opponent" in Медицинский оппонент
- Vol. 27 (3(27)) , 10-15
Диагностические и прогностические цитокиновые маркеры винкристиновой полиневропатии у детей с острым лимфобластным лейкозом. Ковтун О.П., Корякина О.В., Базарный В.В.
Цель исследования заключалась в определении цитокинов плазмы крови и ликвора, претендующих на роль потенциальных диагностических и прогностических маркеров винкристиновой полиневропатии у детей с острым лимфобластным лейкозом. На основании полученных результатов установлены изменения содержания плазменных и ликворных цитокинов в группе пациентов с винкристиновой полиневропатией, что свидетельствует об их связи с развитием данного нейротоксического расстройства. Для совершенствования комплекса обследования детей с винкристиновой полиневропатией разработана диагностическая панель с оптимальным набором цитокинов.